Abstract
On January 25, the FDA approved liraglutide, a glucagon-like-peptide-1 receptor agonist that can improve glycemic control in adults with type 2 diabetes. Drs. Mary Parks and Curtis Rosebraugh discuss the benefits and potentially serious safety concerns associated with this new therapy.
Cite
CITATION STYLE
APA
Parks, M., & Rosebraugh, C. (2010). Weighing Risks and Benefits of Liraglutide — The FDA’s Review of a New Antidiabetic Therapy. New England Journal of Medicine, 362(9), 774–777. https://doi.org/10.1056/nejmp1001578
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free